#China #Suzhou #Porton Advanced #Hualong Biological #MATC Therapy

Porton Advanced Partners with Hualong Biological to Boost MATC Therapy Development

In an exciting development in cancer treatment, Porton Advanced Solutions, a premier contract development and manufacturing organization (CDMO) known for its innovation in advanced therapy medicinal products (ATMPs), has announced a strategic partnership with Hualong Biological. This collaboration is set to expedite the development of Hualong's Multi-Activated T Cell (MATC) therapy targeted at solid tumors.

Accelerated Cell Therapy Development

The partnership will enable Porton Advanced to offer comprehensive CDMO services that cover the entire spectrum of MATC therapy development, from the optimization of manufacturing processes to the preparation of regulatory submissions. This integrated approach promises not only to enhance the efficiency of the therapy's development but also to significantly shorten the timeline for bringing this groundbreaking treatment to clinical trials.

Hualong Biological, recognized for its pioneering work in cancer therapeutics, has a strong foundation for the MATC platform backed by numerous investigator-initiated trials (IITs). These trials have showcased substantial therapeutic advantages across various solid tumor types, making this therapy a promising avenue in oncology.

Mingguang Huang, Chairman of Hualong Biological, expressed enthusiasm about the collaboration, stating, "We are delighted to partner with Porton Advanced. Their extensive CDMO technical know-how and regulatory expertise in cell therapy will undoubtedly enhance our MATC program's development efficiency and the IND preparation timeline. Together, we're committed to advancing this innovative therapy into clinical trials to benefit patients worldwide."

Why This Matters

This collaboration highlights the importance of synergy between organizations in the biotechnology field, especially in the realm of cancer treatment, where time and precision are of the essence. Porton Advanced's capabilities in process development, good manufacturing practice (GMP) compliance, and regulatory support will be pivotal in facilitating Hualong's transition from research to clinical application.

Andrew Chen, CFO of Porton Advanced, remarked, "Collaborating with Hualong Biological marks a strategic expansion of our CDMO services in cell therapy. We are honored to provide regulatory-compliant, high-quality MATC CMC services to support their IND application. Porton Advanced is committed to delivering this cutting-edge therapy to patients faster through our integrated technology platform and regulatory expertise."

Hualong Biological: A Leader in Cell Technology

Founded in 2012, Hualong Biological has emerged as a national high-tech enterprise in China, specializing in cell technology development and applications. The company's strategic vision encompasses areas such as cell storage, research, and therapeutic development, positioning Hualong at the forefront of the cell therapy sector. Their robust expertise in immune and stem cell technologies solidifies their reputation as industry leaders, facilitating a wide range of applications from basic research to clinical implementation.

Porton Advanced: Pioneers in Drug Development

Porton Advanced Solutions is a subsidiary of Porton Pharma Solutions, headquartered in Cranbury, New Jersey. With two GMP facilities located in Suzhou, China, the organization provides a comprehensive range of CDMO solutions for ATMPs. Their services span the drug development journey, from early research through to commercialization.

With a large facility footprint of 215,000 square feet and multiple GMP-compliant production lines, Porton Advanced is well-equipped to support the development of various therapies, including CAR-T, TCR-T, and nucleic acid therapies. The company has successfully assisted clients in securing 18 global IND approvals from regulatory bodies, including the NMPA, FDA, and Medsafe.

Conclusion

The partnership between Porton Advanced and Hualong Biological signifies a pivotal step forward in the realm of cell therapy. By merging their resources and expertise, both companies aim to make significant strides in the battle against cancer, ultimately improving outcomes for patients suffering from solid tumors. This collaboration exemplifies the potential of innovative biotechnology partnerships in transforming healthcare.

For more information about Porton Advanced and their services, visit www.portonadvanced.com.